TLR4 and metabolic dysfunction-associated steatotic liver disease: (2) Polysaccharide inhibits the increase in LPS level, on the one hand, it reduces its stimulation to intestinal epithelial cells, reduces the inflammatory response of intestinal epithelial cells, reduces the damage of tight junction proteins, and improves intestinal barrier function; On the other hand, it reduces the entry of LPS into the liver through the portal vein and the production of LPS–LBP conjugates, which subsequently reduces the response of CD-14 and inhibits the activation of the TLR4 pathway, thereby reducing liver inflammation and relieving NAFLD (Figure 3–Pathway I).